Creo Medical Group gets "great results" from first upper GI use of Speedboat Inject in Europe
News release
by
Creo Medical Group PLC
London, UK
|
June 28, 2023 08:05 AM Eastern Daylight Time
Creo Medical Group PLC (AIM:CREO) CEO Craig Gulliford speaks to Thomas Warner from Proactive after the medical device company announced that the first upper gastrointestinal (GI) procedure in Europe has been carried out using the company's Speedboat Inject product. Gulliford says that the procedure to remove a cancer from a patient's stomach was successfully completed by Adolfo Parra-Blanco at Nottingham University Hospitals, with the "great results... we've come to expect." Gulliford also explains why Creo is now looking for a new Chairman to help develop the company internationally.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
